Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives
John Maher
DOI: https://doi.org/10.2147/OTT.S341179
IF: 4
2023-07-04
OncoTargets and Therapy
Abstract:John Maher 1– 3 1 King's College London, School of Cancer and Pharmaceutical Sciences, CAR Mechanics Lab, Guy's Cancer Centre, Great Maze Pond, London, SE1 9RT, UK; 2 Leucid Bio Ltd., Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK; 3 Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UK Correspondence: John Maher, King's College London, Guy's Hospital, Great Maze Pond, London, SE1 9RT, UK, Tel +0044 207 188 1468, Fax +0044 207 188 0919, Email ; Immunotherapy using chimeric antigen receptor (CAR)-engineered T-cells has achieved unprecedented efficacy in selected hematological cancers. However, solid tumors such as lung cancer impose several additional challenges to the attainment of clinical success using this emerging therapeutic modality. Lung cancer is the biggest cause of cancer-related mortality worldwide, accounting for approximately 1.8 million deaths worldwide each year. Obstacles to the development of CAR T-cell immunotherapy for lung cancer include the selection of safe tumor-selective targets, accounting for the large number of candidates that have been evaluated thus far. Tumor heterogeneity is also a key hurdle, meaning that single target-based approaches are susceptible to therapeutic failure through the emergence of antigen null cancers. There is also a need to enable CAR T-cells to traffic efficiently to sites of disease, to infiltrate tumor deposits and to operate within the hostile tumor microenvironment formed by solid tumors, resisting the onset of exhaustion. Multiple immune, metabolic, physical and chemical barriers operate at the core of malignant lesions, with potential for further heterogeneity and evolution in the face of selective therapeutic pressures. Although the extraordinarily adaptable nature of lung cancers has recently been unmasked, immunotherapy using immune checkpoint blockade can achieve long-term disease control in a small number of patients, establishing clinical proof of concept that immunotherapies can control advanced lung carcinomas. This review summarizes pre-clinical CAR T-cell research that is specifically focused on lung cancer in addition to published and ongoing clinical trial activity. A number of advanced engineering strategies are also described which are designed to bridge the gap to the attainment of meaningful efficacy using genetically engineered T-cells. Keywords: immunotherapy, malignancy, engineered T-cell, pulmonary Lung cancer is the biggest cause of cancer deaths worldwide, accounting for over 18% of mortality attributable to malignant disease. 1 It is estimated that almost 237,000 people were diagnosed with lung cancer in the United States (US) in 2022. 2 Histological subtypes include (i) non-small cell lung cancer (NSCLC – approximately 85% of tumors), which includes adenocarcinoma, squamous cell, large cell and adenosquamous variants, and (ii) small cell lung cancer (SCLC – approximately 15% of tumors). Most patients present with advanced disease, significantly limiting the use of therapeutic options with curative intent. The main modalities used to treat these cancers include surgery, radiotherapy, chemotherapy, targeted therapies using small molecules, tumor-targeted monoclonal antibodies, and immune checkpoint inhibition. However, 130,000 deaths resulted from lung cancer in 2022, making this the leading cause of cancer death in the US. 2 These data highlight a pressing unmet need for new treatment options for these patients. Chimeric antigen receptors (CARs) are synthetic fusion molecules which direct the specificity of immune cells against native cell surface target molecules found on tumors and other cell types. 3 In general, antigen engagement by CARs is direct rather than human leukocyte antigen (HLA)-restricted, akin to the recognition process used by an antibody. As a result, CAR T-cell immunotherapy obviates the need for HLA matching of the receptor to the target. Moreover, HLA downregulation by tumor cells (a common immune evasion mechanism in lung cancer) 4–6 affords no protection to CAR T-cell recognition. CAR technology has been in development since 1987 when T-cell receptor/antibody chimeric receptors were first described. 7 More than 20 years later, several large clinical centers independently described compelling clinical efficacy of CD19-targeted CAR T-cells in the treatment of patients with relapsed refractory B-cell malignancy. 8 More recently, CAR T-cells specific for B-cell maturation antigen (BCMA) have proven to be highly effective in relapsed refractory multiple myeloma. 9 However, solid tumors such as lung cancer remain largely refractory to this approach. Hurdles to the successful transition of this technology for common solid tumors have r -Abstract Truncated-
oncology,biotechnology & applied microbiology